On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies
September 12th 2012A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.
Bisphosphonates Remain Mainstays in Managing Bone Disease: Development of New Agents Is Continuing
September 5th 2012Researchers have identified more than a dozen pathways and factors involving bone disease in patients with multiple myeloma who are at the highest risk of developing complications.
ALK Inhibitors: Moving Rapidly From Discovery to Clinical Approval and Beyond
August 27th 2012There has been stunning progress as preclinical findings of the ALK gene in patients with lung cancer were rapidly translated into the availability of an FDA-approved therapeutic ALK inhibitor, crizotinib.